Diabetes Drug Market Research Report – Global Forecast to 2023

Diabetes Drug Market Scenario
The global diabetes drug market is expected to grow at a CAGR of 6.38% during the forecasted period. Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes, namely type-1 diabetes and type-2 diabetes. During the last decade, there has been a tremendous increase in the number of diabetic patients. According to the International Diabetes Federation, in 2016, it was estimated that 420 million adult populations were suffering from diabetes, which is increasing at a rate of 8.4% and is expected to reach 625 million by 2040. A number of different types of drugs are available in the diabetes drug market, but no available treatment can cure diabetes totally. The global diabetes drug market is majorly driven by an increasing number of diabetic patients. According to research, smoking increases the risk of diabetes; more than 60% of the global population smokes, which has increased the risk of diabetes and contributed to the growth of the diabetes drug market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the diabetes drug market. To meet the increasing demand for the drugs, governments of different countries are providing support to manufacturers. Increasing government support will help to boost the diabetes drug market in the coming future. However, cost issues, strict regulatory rules, and long approval time for drugs may lead to restrained growth of the diabetes drug market.

Intended Audience
- Government and private hospitals
- Blood banks and institutes
- Biotechnological institutes
- Pharmaceutical companies
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Medical Research Laboratories

Figure 1: Global diabetes drug market share, by region
Diabetes Drug Market Segmentation

The global diabetes drug market is segmented on the basis of types, route of administration, drug class, and end users.

On the basis of types, the diabetes drug market is segmented into type-1 diabetes and type-2 diabetes.

On the basis of route of administration, the diabetes drug market is segmented into oral, intravenous and other.

On the basis of drug class, the diabetes drug market segmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, secretagogues, peptide analogs and others. Sensitizers are sub-segmented into thiazolidinediones and biguanides. Secretagogues are further segmented into sulfonylureas and non-sulfonylureas.

On the basis of end users, the diabetes drug market is segmented into hospital & clinics, ambulatory clinics and other.

Diabetes Drug Market Regional Analysis

America dominates the global diabetes drug market owing to large diabetic patient population. According to the WHO, in 2016, 9.6% of total America population were suffering from diabetes. In addition to this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the diabetes drug market in America. Increasing cholesterol level and smoking increases the possibility of causing diabetes. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US had diagnosed with high cholesterol level. Furthermore, increasing awareness among the people regarding different monitoring procedures, rising awareness and well-developed technology have also contributed to the growth of the diabetes drug market.

Europe accounts for the second largest diabetes drug market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the diabetes drug market in Europe.

Asia Pacific is the fastest growing region for the diabetes drug market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.

On the other hand, the Middle East & Africa has the least share in the global diabetes drug market due to presence of poor economy especially in Africa region. Middle East holds the major share in the Middle East & Africa diabetes drug market owing to well-developed healthcare sector and huge healthcare expenditure.

Research Methodology
Key Players for global Diabetes Drug Market

The major player in the global diabetes drug market are Eli Lilly (US), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Biocon (US), Sunpharma (India), Sanofi (France), Novartis (Switzerland), Merck & Co. (US), Pfizer (US), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), Takeda (Japan).

Contents:

TABLE OF CONTENT

Chapter 1. Diabetes Drug Market
Report Prologue

Chapter 2. Diabetes Drug Market
Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Diabetes Drug Market
Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation

Chapter 4. Diabetes Drug Market
Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Diabetes Drug Market
Factor Analysis
5.1 Porters Five Forces Analysis
  5.1.1 Bargaining Power of Suppliers
  5.1.2 Bargaining Power of Buyers
  5.1.3 Threat of New Entrants
  5.1.4 Threat of Substitutes
  5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

**Chapter 6. Global Diabetes Drug Market, by Type**

6.1 Introduction

6.2 Type-1 Diabetes
Market Estimates & Forecast, 2017 – 2023

6.3 Type-2 Diabetes
Market Estimates & Forecast, 2017 – 2023

**Chapter 7. Global Diabetes Drug Market, by Administration**

7.1 Introduction

7.2 Oral
Market Estimates & Forecast, 2017 – 2023

7.3 Intravenous
Market Estimates & Forecast, 2017 – 2023

7.4 Others

**Chapter 8 Global Diabetes Drug Market, by End User**

8.1 Introduction

8.2 Insulin
Market Estimates & Forecast, 2017 – 2023

8.3 Sensitizers
Market Estimates & Forecast, 2017 – 2023

8.4 SGLT-2 Inhibitors
Market Estimates & Forecast, 2017 – 2023

8.5 Alpha-Glucosidase Inhibitors
Market Estimates & Forecast, 2017 – 2023

**Chapter 9 Global Diabetes Drug Market, by End User**

9.1 Introduction

9.2 Hospitals & Clinics
Market Estimates & Forecast, 2017 – 2023

9.3 Ambulatory Clinics
Market Estimates & Forecast, 2017 – 2023

9.4 Others
Market Estimates & Forecast, 2017 – 2023

**Chapter 10. Global Diabetes Drug Market, by Region**

10.1 Introduction

10.2 America

10.2.1 North America
  10.2.1.1 US
  10.2.1.2 Canada

10.2.2 South America

10.3 Europe
10.3.1 Western Europe
  10.3.1.1 Germany
  10.3.1.2 France
  10.3.1.3 Italy
  10.3.1.4 Spain
  10.3.1.5 UK
  10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
  10.4.1 Japan
  10.4.2 China
  10.4.3 India
  10.4.4 Australia
  10.4.5 Republic of Korea
  10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
  10.5.1 United Arab Emirates
  10.5.2 Saudi Arabia
  10.5.3 Oman
  10.5.4 Kuwait
  10.5.5 Qatar
  10.5.6 Rest of the Middle East & Africa

Chapter 11 Diabetes Drug Market Company Landscape
  11.1 Introduction
  11.2 Market Share Analysis
  11.3 Key Development & Strategies
    11.3.1 Key Developments

Chapter 12 Diabetes Drug Market Company Profiles
  12.1 Eli Lilly
    12.1.1 Company Overview
    12.1.2 Product Overview
    12.1.3 Financials
    12.1.4 SWOT Analysis
  12.2 AstraZeneca
    12.2.1 Company Overview
    12.2.2 Product Overview
    12.2.3 Financial Overview
    12.2.4 Key Developments
    12.2.5 SWOT Analysis
  12.3 Abbott
    12.3.1 Company Overview
    12.3.2 Product Overview
    12.3.3 Financial Overview
    12.3.4 Key Development
    12.3.5 SWOT Analysis
  12.4 Biocon
    12.4.1 Company Overview
    12.4.2 Product/Business Segment Overview
Figure 24 Sunpharma: Segmental Revenue
Figure 25 Sunpharma: Geographical Revenue
Figure 26 Merck & Co., Inc.: Key Financials
Figure 27 Merck & Co., Inc.: Segmental Revenue
Figure 28 Merck & Co., Inc.: Geographical Revenue
Figure 29 GlaxoSmithKline plc: Key Financials
Figure 30 GlaxoSmithKline plc: Segmental Revenue
Figure 31 GlaxoSmithKline plc: Geographical Revenue
Figure 32 Sanofi: Key Financials
Figure 33 Sanofi: Segmental Revenue
Figure 34 Sanofi: Geographical Revenue